Evidence map›Paper›PMID 40406134›Full record

ArticleFrontiers in immunology2025

Development and validation of an ARID1A-related immune genes risk model in evaluating prognosis and immune therapeutic efficacy for gastric cancer patients: a translational study.

Jiangtao Zhang, Jingting Li, Shangfeng Yang, Xiaoyan Tang, Chunze Wang, Jiaxing Lin, Qiancheng Chen, Hui Xu, Yuanyuan Ma, Xiaoling Gao

Erratum issuedAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in immunology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Review
  2. Molecular interplay of ARID1A in gastrointestinal cancers.Medical oncology (Northwood, London, England) · 2025
    Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

10 authors.

Jiangtao Zhang *The Clinical Laboratory Center, Hainan General Hospital, Hainan Affiliated Hospital of Hainan, Medical University, Haikou, Hainan, China.
Jingting Li *The Clinical Laboratory Center, Hainan General Hospital, Hainan Affiliated Hospital of Hainan, Medical University, Haikou, Hainan, China.
Shangfeng Yang *Hainan Medical University, Haikou, Hainan, China.
Xiaoyan TangThe Clinical Laboratory Center, Hainan General Hospital, Hainan Affiliated Hospital of Hainan, Medical University, Haikou, Hainan, China.
Chunze WangThe Clinical Laboratory Center, Hainan General Hospital, Hainan Affiliated Hospital of Hainan, Medical University, Haikou, Hainan, China.
Jiaxing LinThe Clinical Laboratory Center, Hainan General Hospital, Hainan Affiliated Hospital of Hainan, Medical University, Haikou, Hainan, China.
Qiancheng ChenHainan Medical University, Haikou, Hainan, China.
Hui XuThe Clinical Laboratory Center, Hainan General Hospital, Hainan Affiliated Hospital of Hainan, Medical University, Haikou, Hainan, China.
Yuanyuan MaSecond Department of Critical Care Medicine, Xi'an Daxing Hospital, Shanxi, China.
Xiaoling GaoThe Clinical Laboratory Center, Hainan General Hospital, Hainan Affiliated Hospital of Hainan, Medical University, Haikou, Hainan, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Mutations in the ARID1A gene, an integral component of the SWI/SNF complex, are prevalent, affecting prognosis and immune response in several malignancies, including gastric cancer (GC). The aim of this study was to identify ARID1A mutation-associated immune genes to construct an ARID1A-related immune gene risk model (ARM). Methods: GSEA and ssGSEA were used to explore the involved biological pathways and the degree of immune cell infiltration, respectively. The prognosis model was constructed by lasso-COX. Protein expression level in tissue was verified by immunohistochemistry. Small molecule compounds were screened using molecular docking techniques and their anticancer value was validated Results: This study revealed immune-related pathways and infiltration level of multiple immune cell types were enriched in the ARID1A Conclusion: ARM provides valuable insights into the prognosis and the effectiveness of ICI, thereby offering a novel strategy for clinical decision. Baicalin and capsaicin are promising potential drugs for GC treatment.

Indexed as

DNA-Binding ProteinsStomach NeoplasmsTranscription FactorsAnimalsBiomarkers, TumorCell Line, TumorFemaleHumansImmune Checkpoint InhibitorsMaleMiceMiddle AgedMolecular Docking SimulationMutationPrognosisTumor MicroenvironmentARID1A protein, humanBiomarkers, TumorDNA-Binding ProteinsImmune Checkpoint InhibitorsTranscription FactorsARID1Agastric cancerimmune gene risk modelmolecular dockingprognosis

Identifiers

PMID40406134
PMCPMC12096169

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.